Substrate-Selective Enzyme Inhibitors.

Trends Pharmacol Sci 2019 Oct 2;40(10):716-718. Epub 2019 Aug 2.

The Salk Institute for Biological Studies, Clayton Foundation Laboratories for Peptide Biology, 10010 N. Torrey Pines Rd, La Jolla, CA 92037, USA. Electronic address:

Enzymes with multiple substrates pose a unique challenge for drug development because of an increased potential for on-target side effects. Maianti and colleagues (Nat. Chem. Biol., 2019) identify novel exo-site inhibitors with abilities to alter the substrate-selectivity of insulin-degrading enzymes (IDE). Their work illuminates new therapeutic avenues for discovering small-molecule enzyme inhibitors and redefines our current understanding of drugging enzymes with multiple substrates.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2019.07.009DOI Listing
October 2019

Publication Analysis

Top Keywords

enzymes multiple
8
multiple substrates
8
enzyme inhibitors
8
therapeutic avenues
4
chem 2019
4
avenues discovering
4
nat chem
4
colleagues nat
4
maianti colleagues
4
enzymes ide
4
side effects
4
effects maianti
4
discovering small-molecule
4
2019 identify
4
novel exo-site
4
alter substrate-selectivity
4
ide work
4
substrate-selectivity insulin-degrading
4
insulin-degrading enzymes
4
abilities alter
4

Similar Publications